financetom
Business
financetom
/
Business
/
Ingersoll Rand Urges Shareholders to Reject Tender Offer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ingersoll Rand Urges Shareholders to Reject Tender Offer
Mar 31, 2025 6:12 AM

08:45 AM EDT, 03/31/2025 (MT Newswires) -- Ingersoll Rand ( IR ) said it urged shareholders to reject an unsolicited "mini-tender" offer by TRC Capital Investment to buy up to 1.5 million shares at $77.50 per share, about 4.27% below the closing price of the company's common stock on March 21, the last trading day before the offer.

Ingersoll Rand ( IR ) said it does not endorse TRC Capital's offer and has no connection with TRC Capital.

Ingersoll Rand ( IR ) shares were down more than 1% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Tech Stocks Flat to Higher Premarket Wednesday
Sector Update: Tech Stocks Flat to Higher Premarket Wednesday
Sep 21, 2024
09:07 AM EDT, 09/18/2024 (MT Newswires) -- Technology stocks were flat to higher premarket Wednesday as the SPDR S&P Semiconductor ETF ( XSD ) was inactive and the Technology Select Sector SPDR Fund ( XLK ) was up 0.4% recently. PowerFleet ( AIOT ) shares advanced by over 5% after the company said it has agreed to acquire Fleet Complete,...
US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month
US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month
Sep 21, 2024
(Reuters) - U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they could sell copycat versions of Novo Nordisk's diabetes drug Ozempic for less than $100 a month. WHY IT'S IMPORTANT Novo Nordisk CEO Lars Jorgensen is set to testify before the Senate Committee on Health, Education, Labor and Pensions (HELP), which Sanders...
Sonnet BioTherapeutics Begins Dosing in Phase 1 Trial of Investigational Cancer Drug
Sonnet BioTherapeutics Begins Dosing in Phase 1 Trial of Investigational Cancer Drug
Sep 21, 2024
09:01 AM EDT, 09/18/2024 (MT Newswires) -- Sonnet BioTherapeutics Holdings ( SONN ) said Wednesday it has completed patient enrollment and begun dosing in the phase 1 trial of its investigational cancer therapy, SON-1010, for advanced solid tumors. The company said it expects to report topline results in Q4. The study, which involves 24 adult patients, is an open-label trial...
Qualcomm's EU Fine Reduced Slightly But Court Upholds Antitrust Violations
Qualcomm's EU Fine Reduced Slightly But Court Upholds Antitrust Violations
Sep 21, 2024
Qualcomm Incorporated ( QCOM ) shares are trading marginally higher on Wednesday in the premarket session. Qualcomm’s EU antitrust fine was largely upheld by Europe’s second-highest Court, with a slight reduction from 242 million euros to 238.7 million euros ($265.58 million), the Luxembourg-based General Court said. Qualcomm ( QCOM ), a U.S. company known for its cellular and wireless technologies,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved